SKM-1 Cells

The SKM-1 cell line is a human leukemia model established from the peripheral blood of a patient with acute monoblastic leukemia that developed from myelodysplastic syndrome (MDS). These cells exhibit immature morphological features, such as a high nucleus-to-cytoplasm ratio and fine azurophilic granules, making them an excellent model for studying the molecular and cellular mechanisms of leukemia, particularly the transition from MDS to acute myeloid leukemia (AML).

Genetic analysis of SKM-1 has revealed important chromosomal abnormalities, including del(9)(q13;q22) and der(17)t(17:?)(p13:?); the latter alteration involves the p53 gene, which is overexpressed and harbors mutations in this cell line. These findings highlight the role of p53 in clonal evolution and progression of myeloid malignancies. SKM-1 cells are also characterized by their expression of myelomonocytic markers, including CD4, CD13, and CD33, as well as their positivity for butyrate esterase activity, which aligns with their monoblastic lineage.

This cell line is widely used in research on leukemogenesis, drug resistance, and the molecular pathways underlying leukemia. For instance, SKM-1 provides a platform for exploring the impacts of p53 dysfunction and other genetic lesions on cell proliferation and therapeutic response. It also serves as a model for investigating novel therapeutic strategies for myelodysplastic syndromes and secondary AML.